Strides Pharma Declares Record Date For Rs 2.50/Sh Dividend, Shares Rise 213% In 1-Yr

Small cap pharmaceuticals sector company Strides Pharma Science Ltd shares gained nearly 37% in last 1-month. Today the pharmaceuticals sector company fixed September 9, 2024 as the record date for final dividend of Rs 2.50/- per equity share of the face value of Rs 10/- each for the financial year 2024. Current market price of Strides Pharma Science Ltd shares on BSE is Rs 1302.10 per share with decline of 1.89% at the time of writing the story. Strides Pharma Science has a market capitalisation of Rs 11,973.88 crore. Strides Pharma Science shares offered return of 100% year-to-date (YTD). More details below:

Strides Pharma Science Sets Record Date For Final Dividend: According to the BSE filing of Strides Pharma Science dated August 22, 2024, "As informed by the Company on May 22, 2024, Board of Directors of the Company have recommended a Final Dividend of Rs. 2.50/- per equity share of Face Value of Rs 10/- each for FY24. Record Date for the purpose of said Dividend is Monday, September 9, 2024. Dividend once approved by the Members in the ensuing AGM, shall be paid within 30 days from the date of such approval."

Strides Pharma Science Shares Performance: The 52-week high price of Strides Pharma Science shares on BSE is Rs 1346.95 per share (as on 22/08/2024) and 52-week low price is Rs 416.95 per share (as on 23/08/2023), respectively. Strides Pharma Science shares offered return of 213% in last 1-year, gave return of 284% in last 2-years, and offered return of 117% in last 3-years.

Strides Pharma Financials: The Bengaluru-based pharma firm declared its net profit at Rs 68.3 crore for Q1FY25 as against the loss of Rs 9.4 crore in the corresponding quarter of last year (Q1FY24). Strides Pharma's metrics witnessed improvement sequentially as well. The revenue for the Q1FY25 was declared at Rs 1,085.7 crore, up 16.6% year-on-year (Y-o-Y). "The company achieved critical thresholds of 20% EBITDA margin, Rs 683 million of reported PAT and 2.3 times of Debt/EBITDA ratio. The company has increased its focus on digitisation, automation, and ESG for better compliance and business outcomes," according to the BSE filing of Strides Pharma.

About: Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor‐ funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" productssold in over 100 countries. Additional information is available at the Company's website at www.strides.com.

Disclaimer:

The stock highlights the shares rally and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.